Routine Ketorolac Use for Postoperative Pain Does Not Increase Bleeding Risk After Hysterectomy

<b>Background/Objective:</b> Ketorolac is an effective alternative and addition to opioids for postoperative pain control; however, there is concern of perioperative bleeding risk with its use. Within gynecology, this risk has not yet been explored in the context of hysterectomy. This study aimed to evaluate the risk of postoperative bleeding complications with ketorolac administration in the context of hysterectomy. <b>Methods:</b> This was a retrospective cohort study that included all patients who underwent hysterectomy for benign indications between 2015 and 2024 at a quaternary care academic hospital. Inclusion criteria were any type of hysterectomy during the study period, while exclusion criteria were malignancy and peripartum status. Complication data for up to thirty days post operation were collected. Multivariable regression analysis, including age, American Society of Anesthesiology category, use of celecoxib before surgery, anticoagulant treatment, uterus size, surgical approach, increased surgical complexity, and lysis of adhesions, was performed to identify the adjusted odds of postoperative bleeding complications. The primary outcome was a composite of any postoperative bleeding complications by use of postoperative ketorolac, including postoperative transfusion, readmission, or reoperation for bleeding. <b>Results:</b> In total, 4236 patients underwent hysterectomy for benign indications during our study period, of which 76% (<i>n</i> = 3236) received ketorolac postoperatively. The composite postoperative bleeding rate was lower in the ketorolac group (2.1% vs. 4.1%, <i>p</i> = 0.001). There was no association between ketorolac use and risk of postoperative bleeding in multivariable regression analysis (aOR 1.02, 95% CI 0.36-2.88). There was no difference in overall intraoperative or perioperative complications (<i>p</i> = 0.070 for both). Major perioperative complications were less likely in the ketorolac group (<i>p</i> = 0.046). Additionally, there were no differences in postoperative complications except for ileus, which was less likely in the ketorolac group (<i>p</i> = 0.034). <b>Conclusions:</b> Ketorolac administration was not associated with a higher risk of bleeding complications after hysterectomy, including when celecoxib was used preoperatively as part of an enhanced recovery protocol. It may safely be administered as an opioid-sparing pain medication in this setting.